Cantor Fitzgerald Analysts Boost Earnings Estimates for Krystal Biotech, Inc. (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2024 earnings estimates for shares of Krystal Biotech in a research report issued on Tuesday, May 7th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will post earnings per share of $4.00 for the year, up from their previous estimate of $3.84. The consensus estimate for Krystal Biotech's current full-year earnings is $1.82 per share.

Several other research analysts have also recently weighed in on KRYS. HC Wainwright reissued a "buy" rating and set a $200.00 price objective on shares of Krystal Biotech in a report on Monday. Guggenheim upped their price target on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a "buy" rating in a research report on Tuesday, February 27th. Stifel Nicolaus reiterated a "buy" rating and issued a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Citigroup upped their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a "buy" rating in a research report on Tuesday, February 27th. Finally, William Blair reiterated an "outperform" rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $171.00.

Krystal Biotech Stock Down 2.5 %

Krystal Biotech stock traded down $3.98 during trading hours on Friday, hitting $154.76. The stock had a trading volume of 186,317 shares, compared to its average volume of 360,131. The stock has a market capitalization of $4.42 billion, a P/E ratio of 84.89 and a beta of 0.91. Krystal Biotech has a 12-month low of $86.03 and a 12-month high of $189.97. The stock's 50-day moving average price is $168.75 and its 200-day moving average price is $134.44.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by ($0.17). The company had revenue of $45.25 million for the quarter, compared to the consensus estimate of $47.37 million. Krystal Biotech's quarterly revenue was up 452400.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.76) EPS.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC raised its position in Krystal Biotech by 112.5% during the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company's stock worth $89,862,000 after buying an additional 383,495 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Krystal Biotech in the third quarter valued at about $14,272,000. Charles Schwab Investment Management Inc. boosted its holdings in Krystal Biotech by 10.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 179,780 shares of the company's stock valued at $20,854,000 after purchasing an additional 17,614 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Krystal Biotech by 40.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company's stock valued at $278,416,000 after buying an additional 693,852 shares during the period. Finally, Trexquant Investment LP increased its holdings in shares of Krystal Biotech by 8.8% during the 3rd quarter. Trexquant Investment LP now owns 8,113 shares of the company's stock worth $941,000 after buying an additional 657 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CAO Kathryn Romano sold 8,087 shares of the firm's stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $136.91, for a total value of $1,107,191.17. Following the transaction, the chief accounting officer now owns 12,556 shares of the company's stock, valued at approximately $1,719,041.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 8,087 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $136.91, for a total transaction of $1,107,191.17. Following the transaction, the chief accounting officer now owns 12,556 shares in the company, valued at $1,719,041.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,087 shares of company stock valued at $6,210,591. 14.10% of the stock is currently owned by company insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).